吉西他滨联合参一胶囊治疗老年晚期非小细胞肺癌临床观察

The Clinical Effect of Gemcitabine Combined with Shenyi Capsule on Elderly Advand Non-small Cell Lung Cancer Patients

目的观察吉西他滨联合参一胶囊治疗老年晚期非小细胞肺癌(NSCLC)的疗效与不良反应。方法对27例老年晚期NSCLC患者采用国产吉西他滨1000 mg/m2,第1、8天静脉滴注,4周方案。化疗同时服用参一胶囊每日2次,每次2粒,4周为1个疗程。结果 27例患者中完全缓解2例,部分缓解10例,稳定期11例,进展期4例。总有效率44.4%,临床受益率85.1%。不良反应以白细胞及血小板下降为主,均可耐受。结论吉西他滨联合参一胶囊治疗老年晚期非小细胞肺癌疗效好,可明显改善生活质量,延长生存时间,不良反应轻,患者可耐受。

Objective To explore effect and side effect of Gemcitabine combined with shenyi capsule on elderly advanced non-small cell lung cancer（ NSCLC） . Methods 27 patients received gemcitabine （1000mg/m2 d1,8 intravenous dripping,4 weeks） ,and were given shenyi capsule meanwhile（ 2 capsules per time,2 times per day,4 weeks as one period） . Results All patients can sit for evaluation and there were 2 patients of CR,10 patients of PR,11 patients of SD,4 patients of PD. Total efficacy was 44. 4% ,clinical benefit rate 85.1% . The major side effect were WBC and PLT decrease,but all within tolerance. Conclusion Gemcitabinecombined with shenyi capsule has a good efficacy on elderly advanced NSCLC patients,can improve life quality,prolong surrival time,and all patients can endure the side effect.